Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

7.130 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.130
Bid (Size) 7.080 (4)
Ask (Size) 7.150 (11)
Prev. Close 7.130
Today's Range 7.130 - 7.130
52wk Range 1.080 - 7.190
Shares Outstanding 42,705,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
From G1 Therapeutics
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
+129.26%
+129.26%
1 Month
+0.56%
+0.56%
3 Month
+148.43%
+148.43%
6 Month
+114.76%
+114.76%
1 Year
+321.89%
+321.89%

More News

Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
Via InvestorPlace
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
From Brodsky & Smith LLC
Via GlobeNewswire
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Jumps Over 3%; Upstart Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates
Via Benzinga
Topics Earnings
Exposures Financial
GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Pharmacosmos Group to Acquire G1 Therapeutics
From G1 Therapeutics; Pharmacosmos
Via GlobeNewswire
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
Via InvestorPlace
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
Via InvestorPlace
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
Via InvestorPlace
Exposures Product Safety
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Via Benzinga
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
Via Benzinga
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
From G1 Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.